The effect of Diltiazem on the major adverse cardiac events after percutaneous coronary intervention

Abstract

Objective To detect the impact of Diltiazem on the major adverse cardiac events (MACE) in six months after percutaneous coronary intervention (PCI). Methods A total of 192 patients after PCI with coronary atherosclerotic heart disease were enrolled in this study. The patients were randomly divided into Diltiazem therapy group (101 patients) and non-Diltiazem therapy group (91 patients). The high-sensitivity C-reactive protein (hs-CRP) was assessed before and 24 h after PCI, and the incidence of Major adverse cardiovascular events(MACEs) were assessed at the sixth month after PCI. Results Compared with before PCI, hs-CRP level increased significantly in both group after PCI (P<0.01), but hs-CRP level was lower in Diltiazem therapy group than in non-Diltiazem therapy group (P<0.05 ). Compared with non-Diltiazem therapy group, there was lower incidence of MACEs during six months follow-up in Diltiazem therapy group. Conclusions Diltiazem can decrease the incidence of MACEs during six months after PCI. Key words: Coronary diseose; Angioplasty, transluminal, percutaneous coronary; Calcium channel blockers; C-reactive protein